No description available.

No description available.

Enterococci are found in soil, sewage, food, water, and are commensal to the gastrointestinal tracts of mammals, insects, and birds. Enterococci often become nosocomial pathogens that cause a wide variety of diseases including urinary tract infections, endocarditis, and septicemia. These infections are often difficult to treat with antibiotics because most of the nosocomial strains are multi-drug resistant. Enterococcal plasmids function as reservoirs for resistance genes because they are extremely stable, allow for specific and efficient transfer, and can acquire resistance determinants from the chromosome and other plasmids. Additionally, enterococcal plasmids transfer across species boundaries transferring resistance genes like vancomycin to species like Staphylococcus aureus. There are two types of enterococcal plasmids, pheromone-responsive and broad host range. Pheromone-responsive plasmids are extremely stable, have a limited host range, and are primarily found in Enterococcus faecalis. Broad host range plasmids of E. faecalis and Enterococcus faecium are less stable than pheromone-responsive plasmids, but have an expanded host range into other Gram-positive species. E. faecalis has at least 25 known pheromone-responsive conjugative plasmids. One of the most extensively studied pheromone-responsive conjugative plasmids, pCF10. Conjugation of pCF10 from donor to recipient cell is induced by pheromone cCF10. cCF10 is contained within n the lipoprotein signal sequence encoded by the E. faecalis chromosomal gene ccfA. The lipoprotein signal sequence is processed by a series of proteolytic cleavage events to produce mature cCF10. Maturation of pheromone cCF10 produces three peptides: pre-cCF10 (CcfA1-22), cCF10 (CcfA13-19), and CcfA1-12. Cells containing pCF10 continue to produce cell membrane associated precursor pheromone of cCF10 (pre-cCF10), as well as, secreted and cell wall-associated cCF10. The presence of cCF10 does not self-induce conjugation by the donor cell because of two inhibitory molecules, PrgY and iCF10. Transmembrane protein PrgY is encoded by pCF10 and reduces cell wall associated cCF10, iCF10 is a pCF10 encoded inhibitory peptide (AITLIFI) that binds to PrgX, preventing cCF10 binding. While cCF10 controls pCF10 conjugation, pre-cCF10 controls host range of pCF10 by interacting with pCF10 replication initiation protein PrgW. cCF10 can initiate conjugation and mobilize the transfer of plasmids into other species, including Lactococcus lactis, but pCF10 cannot be maintained within the cell. However, if L. lactis is engineered to produce pre-cCF10, pCF10 can be maintained. The pre-cCF10 involvement in the establishment of pCF10 into other species might be related to the observation that it binds to the pCF10 replication initiation protein PrgW. By in vitro affinity chromatography experiments, interaction of cCF10 and pre-cCF10 with PrgW induced changes in PrgW mobility in gel electrophoresis that caused by formation of doublets and formation of aggregates which were thought to be mediated by disulfide bonds. Initial evidence of regulation of PrgW conformation by disulfide bonds was seen in Western blots of E. faecalis whole cell lysates where PrgW migration is sensitive to reduction. Sequence alignment comparisons between PrgW and a group of 54 of 59 known RepA_N superfamily proteins in E. faecalis revealed three highly conserved cysteines; these RepA_N proteins had a limited host range to E. faecalis. To study the importance of theses cysteines in pCF10 maintenance and host range limitation, prgW single, double, and triple cysteine to alanine (C to A) substitutions were generated. The cysteine mutant prgW was cloned into a plasmid functioning as either a contained the prgW alone (pORI10), or containing prgW with genes necessary for efficient pCF10 maintenance (pMSP6050). While all cysteine mutant plasmids of pORI10 and pMSP6050 were still capable of replicating in E. faecalis, the plasmid stability and copy number decreased, providing evidence that the cysteines were important to PrgW function. Additionally, Western blot analysis revealed PrgW C to A substitutions decreased PrgW aggregation. Mutations of PrgW cysteines reduced pMSP6050 stability and aggregation, but increased host range to L. lactis. Both L. lactis engineered to produce pre-cCF10 and the mutation of the conserved cysteines of PrgW extended host range of pMSP6050 into L. lactis. These data taken together with the observations that pre-cCF10 induced PrgW aggregation suggested that pre-cCF10 regulated the activity of the PrgW replication initiation protein through disulfide bonds. While the conserved cysteines of RepA_N proteins are found only in E. faecalis, phylogenetic analysis revealed that RepA_N homologs lacking the three cysteines are also found in E. faecium or S. aureus, suggesting that the host range of multiple plasmids might be affected by cysteine bond formation. Phylogenetic analysis also showed that the RepA_N proteins of enterococci and staphylococci appear to have evolved to determine host range based on the presence of two of the three conserved cysteines. Modular evolution of E. faecalis plasmids, like pCF10, that contained RepA_N proteins with three conserved cysteines, might have determined the fate of the plasmid as a limited host range, stable reservoir for antibiotic resistance. / Microbiology and Immunology

The enzymatic conversion of lignocellulosic biomass into fermentable sugars is a promising approach for producing renewable fuels and chemicals. However, the cost of the fungal enzymes usually employed in this process remains a significant bottleneck for manufacturing low value-added products from biomass. A potential route to increase hydrolysis yield, and thereby to reduce hydrolysis cost, would be to supplement the fungal enzymes with their lacking enzymatic activities, such as Beta-glucosidase. To produce such enzymes at a low cost, the bacterium Escherichia coli is a strong contender, owing to its ability to grow rapidly on simple and inexpensive media, and to achieve high levels of productivity. Nevertheless, there is hardly any techno-economic analysis of low-value protein production using E. coli in the literature, and, more generally, there are very few techno-economic analyses of low-value protein production ever reported, with the exception of cellulase production by Trichoderma reesei. In particular, the biotechnological application of recombinant E. coli platforms equipped with toxin-antitoxin systems to ensure plasmid stability remains largely unexplored, and its economic impact, unknown. As such, this work presents a comprehensive techno-economic analysis of the industrial production of a low-cost enzyme (Beta-glucosidase) using both E. coli BL21(DE3) and E. coli SE1, a modified BL21(DE3) strain equipped with a toxin-antitoxin system for plasmid maintenance. Moreover, this study describes the actual cloning and expression of a Beta-glucosidase enzyme into E. coli BL21(DE3) and E. coli SE1, and the development of a novel inoculum production scheme that exploits the features of the SE1 strain, based on repeatedly recycling a fraction of the inoculum cells. The results of the techno-economic analysis project an enzyme production cost of 316 US$/kg in the baseline scenario, which is considerably higher than the values reported in the literature for the fungal cocktails. The facility-dependent cost, which is strongly associated with the cost of equipment, accounts for roughly half of the estimated cost, while the cost of raw materials, especially IPTG and glucose, and the cost of consumables are all quite significant. However, the simulation of multiple scenarios and optimization measures suggest that the enzyme cost can be substantially reduced on many fronts, such as: substituting the carbon source for cheaper alternatives; reducing the amount of IPTG used for induction; using an E. coli strain capable of extracellular production; or eliminating the steps of concentration and stabilization of the enzyme, in the case of on-site enzyme utilization. Developing E. coli strains capable of high rEnzyme volumetric productivities can also significantly reduce the cost of the enzyme, up to approximately 135 US$/kg in the scenario of highest productivity. In addition, based on the experimental results with the E. coli SE1 system, an inoculum recycle strategy that avoids the need of an extensive seed train was simulated, resulting in a significant reduction of the enzyme cost. Finally, the combination of multiple process improvements could lead to an enzyme cost near 20 US$/kg of protein, which comes close to the cost of fungal cellulases and demonstrates the great biotechnological potential of recombinant E. coli platforms. / A conversão enzimática de biomassa lignocelulósica em açúcares fermentescíveis é uma via promissora para a produção de combustíveis e produtos químicos renováveis. No entanto, o custo das enzimas fúngicas usualmente empregadas nesse processo permanece um gargalo significativo para a fabricação de produtos de baixo valor agregado a partir de biomassa. Uma possível estratégia para aumentar o rendimento da hidrólise e, assim, reduzir seu custo, seria suplementar as enzimas fúngicas com suas atividades enzimáticas deficientes, tais como a enzima Beta-glicosidase. Para produzir tais enzimas a um baixo custo, a bactéria Escherichia coli é uma forte candidata, dada a sua capacidade de crescer rapidamente em meios simples e baratos e de alcançar altos níveis de produtividade. No entanto, na literatura quase não há análises técnico-econômicas de produção de proteínas de baixo valor agregado utilizando E. coli e, de forma mais geral, há muito poucas análises técnico-econômicas de produção de proteínas de baixo valor agregado publicadas, com exceção da produção de celulases por Trichoderma reesei. Em particular, a aplicação biotecnológica de plataformas recombinantes baseadas em E. coli dotadas de sistemas toxina-antitoxina para garantir a estabilidade plasmidial segue em larga medida inexplorada, e seu impacto econômico, desconhecido. Assim, este trabalho apresenta uma análise técnico-econômica abrangente da produção industrial de uma enzima de baixo custo (Beta-glicosidase) usando E. coli BL21 (DE3) e E. coli SE1, uma cepa de BL21 (DE3) modificada que possui um sistema toxina-antitoxina para manutenção plasmidial. Além disso, este estudo descreve a clonagem e expressão de uma Beta-glicosidase em E. coli BL21 (DE3) e E. coli SE1, assim como o desenvolvimento de um novo método de produção de inóculo que tira proveito das peculiaridades da linhagem SE1, baseado em reciclar repetidamente uma fração das células do inóculo. Os resultados da análise técnico-econômica apontam para um custo de produção da enzima de 316 US$/kg no cenário-base, valor consideravelmente superior àqueles relatados na literatura para os coquetéis fúngicos. Os custos de overhead da planta, que estão fortemente associados ao custo de aquisição dos equipamentos, são responsáveis por aproximadamente metade do custo total, enquanto o custo de matérias-primas, especialmente IPTG e glicose, e o custo de consumíveis são bastante significativos. Porém, a simulação de múltiplos cenários e medidas de otimização sugerem que o custo da enzima pode ser substancialmente reduzido em muitas frentes, tais como: a substituição da fonte de carbono por alternativas mais baratas; a redução da quantidade de IPTG usado para indução; a utilização de cepas capazes de produzir a enzima extracelularmente; ou a eliminação das etapas de concentração e estabilização da enzima, em caso de utilização da enzima in situ. O desenvolvimento de cepas de E. coli capazes de atingir altas produtividades volumétricas de rEnzima também pode reduzir significativamente o seu custo, chegando a US$ 135/kg no cenário de maior produtividade. Com base nos resultados experimentais com a linhagem E. coli SE1, uma estratégia de reciclagem de inóculo que evita a necessidade de um extenso trem de inoculação também foi simulada, gerando significativa diminuição do custo da enzima. Por fim, a combinação de múltiplas melhorias no processo poderia levar a um custo de enzima em torno de 20 US$/kg de proteína, valor que se aproxima do custo das celulases fúngicas e que demonstra o grande potencial biotecnológico de plataformas de expressão baseadas em E. coli recombinante.

Os neutrófilos são glóbulos brancos do sangue e primeira linha de defesa contra as bactérias. A proliferação destas células é principalmente controlada pelo Fator Estimulador de Colônia de Granulócito (G-CSF). O G-CSF humano recombinante (rhG-CSF) é um medicamento amplamente utilizado para tratar a neutropenia, condição caracterizada pela contagem de neutrófilos abaixo de 1.500/mm3. O rhG-CSF já foi obtido no Centro de Biotecnologia do Instituto Butantan em E. coli como corpos de inclusão (CI), reportando-se instabilidade do plasmídeo e baixo rendimento. Neste trabalho, o plasmídeo pARKAN-I foi avaliado para produzir rhG-CSF em E. coli e viabilizar sua obtenção em biorreator. Esse vetor carrega a sequência pAR, inserida para aumentar sua estabilidade. E. coli BL21 (DE3) Star pLysS transformada com pARKAN-I/rhG-CSF foi cultivada em frascos agitados para avaliação da estabilidade do plasmídeo em meios complexos (2YT e de autoindução) e quimicamente definido (HDF). Avaliou-se a influência de indutores (IPTG e lactose), glicose e antibióticos sobre a estabilidade plasmidial. A fim de se obter material para purificação, foram realizados cultivos em biorreator com meio de autoindução sem antibióticos em modo batelada e HDF com antibióticos em modo batelada alimentada, a 30ºC, 30% de oxigênio e pH 6,8. As etapas de purificação incluíram: lise em homogeneizador contínuo de alta pressão, lavagens, solubilização e renaturação dos CI, e cromatografia de troca catiônica em SP-Sepharose. Avaliaram-se três métodos de renaturação: diafiltração, diálise e diluição. A estabilidade do plasmídeo foi avaliada pela percentagem de colônias obtidas em placas de LB-ágar com antibiótico em relação às colônias que cresceram nas placas de LB-ágar sem antibiótico. A identidade proteica foi determinada por SDS-PAGE e Western Blotting. A pureza relativa e a produção específica do rhG-CSF foram determinadas por densitometria das bandas da eletroforese. A quantificação proteica foi feita pelo método do ácido bicinconínico. Nos cultivos em frascos com meio 2YT sem glicose, o crescimento foi mais lento, porém a fase exponencial mais prolongada, alcançando concentração celular (Cx) mais elevada (2,56 g/L) do que as culturas com glicose (Cx1,35 g/L), que cresceram mais rápido e chegaram primeiro à fase estacionária. O cultivo com meio de autoindução proporcionou crescimento similar ao do meio 2YT sem glicose. Em meio HDF, os cultivos tiveram o crescimento mais lento e menor Cx (0,94 g/L). Os meios 2YT e de autoindução mostraram 100% de colônias resistentes à canamicina antes e após indução, exceto o 2YT sem antibiótico e sem glicose, com 97,5% e 94,1% após 6 e 8 h de indução, respectivamente, coincidindo com a maior produção de rhG-CSF. Em frascos, o meio HDF com antibiótico teve 93% de colônias resistentes antes da indução dos cultivos em frascos, diminuindo até 85% após 4 h de indução, com baixa produção do rhG-CSF, verificada apenas por Western Blotting. Os cultivos em biorreator mostraram baixa velocidade específica de crescimento (0,30 h-1), porém elevada Cx e produção de rhG-CSF, sendo superior no meio de autoindução, que também resultou mais barato do que o HDF. O método de diluição em tampão tris 20 mM pH 8,0 com EDTA 2 mM, Triton X-100 0,1% e glicerol 10% apresentou maior percentagem de renaturação. Foi estabelecido um processo de purificação que permitiu obter rhG-CSF com 87% de pureza, integridade estrutural e atividade biológica. O plasmídeo pARKAN-I, vetor sem restrições de propriedade intelectual e proteção de patente, mostrou alta estabilidade nos meios complexos avaliados, tanto em frasco como em biorreator, permitindo produzir rhG-CSF em larga escala sem adição de antibióticos ao meio de cultura, o que reduziu o custo do processo de obtenção. / Neutrophils are white blood cells and part of the first line of defense against bacteria. The proliferation of these cells is mainly controlled by the Granulocyte Colony Stimulating Factor (GCSF). Recombinant human G-CSF (rhG-CSF) is widely used to treat neutropenia, condition characterized by a neutrophil count below 1,500/ mm3. The rhG-CSF was already obtained at the Biotechnology Center of the Butantan Institute in E. coli as inclusion bodies (IB), but plasmid instability and low yield were reported. In this work, the plasmid pARKAN-I was evaluated to produce rhG-CSF in E. coli and enable the bioreactor production. This vector carries a Par sequence, inserted to increase its stability. E. coli BL21 (DE3) Star pLysS transformed with pARKAN-I / rhG-CSF was grown in shaken flasks to evaluate the plasmid stability in complex (2YT and autoinduction) and chemically defined (HDF) media. Also, the influence of inducers (IPTG and lactose), the addition of glucose and the presence of antibiotics on the plasmid stability were evaluated. In order to obtain material for rhG-CSF purification, a batch culture with autoinduction medium without antibiotic and fed-batch culture HDF medium with antibiotic were performance in bioreactor at 30º C, 30% oxygen and pH 6.8. The purification steps included: lysis in high pressure continuous homogenizer, wash, solubiliztion and refolding of IB and cation exchange chromatography in SP-Sepharose. Three refolding methods were evaluated: diafiltration, dialysis and dilution. Plasmid stability was evaluated by the percentage of colonies on LB-agar plates with antibiotic in relation to the colonies that grew on LB-agar plates without antibiotics. Protein identity was determined by SDS-PAGE and Western Blotting. Relative purity and specific production of rhG-CSF were determined by densitometry of SDS-PAGE bands. Protein quantification was performed by the bicinchoninic acid method. In shaken flask cultures with 2YT medium without glucose, the growth was slower, but the exponential phase was longer, reaching higher cell concentration (Cx=2.56 g/L) than the cultures in 2YT medium with glucose (Cx≈1.35 g/L), which grew faster and reached the stationary phase earlier. Cultures with autoinduction medium provided similar growth to the 2YT medium without glucose. Cultures with HDF medium displayed slower growth and lower Cx (0.94 g/L). Shaken flask cultures with 2YT and autoinduction media showed 100% of kanamycin resistant colonies before and after induction, except for 2YT without antibiotic and without glucose, which presented 97.5% and 94.1% of kanamycin resistant colonies after 6 and 8 h of induction, respectively, despite being the medium with higher production of rhG-CSF. In flasks, HDF medium with antibiotic presented 93% of kanamycin resistant colonies before induction, decreasing to 85% after 4 h of induction, the rhGCSF production was very low, and could be verified only by Western Blotting. Bioreactor cultivations showed low specific growth rate (0.30 h-1), but high cell density and recombinant protein production. The rhG-CSF production was higher in autoinduction medium, which was cheaper than HDF. The dilution method using 20 mM tris buffer pH 8.0, 2 mM EDTA, 0.1% Triton X-100 and 10% glycerol showed the highest percentage of refolding. A purification process was established and allowed to obtain rhG-CSF with 87% purity, structural integrity and biological activity. The expression vector pARKAN-I, which is free of intellectual property and patent protection, showed high plasmid stability in the complex media evaluated in flask and bioreactor and allowed to produce rhG-CSF in large scale without addition of antibiotics to the culture medium, reducing the cost of the production process.